CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma.

Ghassan K Abou-Alfa Susan M Geyer Andrew B Nixon Federico Innocenti Qian Shi Priya U Kumthekar Sawyer Jacobson Imane El Dika Amin Yaqubie Juan Lopez Binhui Huang Yi-Wei Tang Yujia Wen Lawrence H Schwartz Anthony B El-Khoueiry Jennifer J Knox Lakshmi Rajdev Monica M Bertagnolli Jeffrey A Meyerhardt Eileen M O'Reilly Alan P Venook

Published in: Cancer research communications (2024)

Sorafenib therapy for HCC may impact HCV replication and viral gene expression. In HCV-positive patients accrued to CLAGB 80802 phase III study evaluating the addition of doxorubicin to sorafenib, HCV titer levels were evaluated at baseline and different timepoints. Sorafenib did not impact HCV titer levels. Despite an improved PFS in patients with detectable higher level HCV titers at baseline, no difference in OS was noted.

Keyphrases

hepatitis c virus
gene expression
phase iii
human immunodeficiency virus
clinical trial
end stage renal disease
open label
dna methylation
newly diagnosed
sars cov
cancer therapy
prognostic factors
patient reported outcomes
phase ii
antiretroviral therapy